MISSION-03. Uncomparable Speed

Unparalleled speed and presence as an international standard


The Incomparable Speed of System Bio-Medicine


Speedy and low cost drug development system

In the competition to globalize, it is said that development of pharmaceutical products will cost 20 billion yen in 2010. LSBM is advancing the drug discovery of genome antibody that shortens this cost and time to 1/3 by making full use of the technology of system biomedical science. This is a revolutionary development system that integrates the expression of a chemical substance receptor complex which is a target of pharmaceuticals, the selection of a functional monoclonal antibody binding to it, and development as a pharmaceutical product. Unlike traditional drug development, instead of finding a drug by chance, we select proteins targeted by drugs in human genes. This is expressed using baculovirus, and a monoclonal antibody that reliably acts on the target protein is selected from a library with a variety of astronomical numbers. Antibody is essentially a human protein, technologies to develop safely as medicinal products have greatly advanced. By combining these technologies with genomic antibody drug discovery, the conventional 8-step process can be made in 3 steps, enabling rapid development of an unprecedented pharmaceutical product. We can simultaneously develop drugs to a large number of target proteins, so we will diversify the risks associated with drug development and increase the likelihood of success.


The world’s de facto standard of systematic analysis of chemical substance receptors

In drug development, the receptor of the cell membrane called GPCR and the nuclear receptor that binds hormones etc. are the most important targets. LSBM leads the world by systematic analysis of two receptors. We succeeded in reconstituting GPCR on insect virus surface and constructed a technology to analyze all 1,000 GPCR genes. We also bought competing Montreal university patents and established worldwide patents. About 48 genes of nuclear receptor, we have tied up with French Pasteur Institute and Howard Hughes Institute of University of Texas in the USA, all genes are collected in LSBM, and we are preparing monoclonal antibodies. It is a technology system that has already become the de facto standard of the world.


Create innovative new drugs from orphan receptor genes

Among the myriad chemicals in nature, those with human receptor genes act in trace amounts and play an important role. It is estimated that about 5,000 genes respond to chemical substances such as drugs from genome decoding. The target of traditional medicines has been said to be 500, but there are ten times the unknown orphan receptor there. LSBM is pursuing technology development that comprehensively expresses an important chemical substance receptor family related to nuclear and membrane medicines and foods, enabling the development of completely new drugs and the like.